Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents

Valeria Santini*, António Almeida, Aristoteles Giagounidis, Stefanie Gröpper, Anna Jonasova, Norbert Vey, Ghulam J. Mufti, Rena Buckstein, Moshe Mittelman, Uwe Platzbecker, Ofer Shpilberg, Ron Ram, Consuelo Del Cañizo, Norbert Gattermann, Keiya Ozawa, Alberto Risueño, Kyle J. MacBeth, Jianhua Zhong, Francis Séguy, Albert HoenekoppC. L. Beach, Pierre Fenaux

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

180 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents'. Together they form a unique fingerprint.

Medicine and Dentistry